Lipella Pharmaceuticals Inc. (LIPO)
LIPO moved a median of -0.45% 30 minutes after news, and 0.00% by the close. How LIPO actually reacts to news — the realized, point-in-time move the market made, measured across 177 labeled events over the last three years with zero look-ahead.
LIPO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.15% | 25% | 145 |
| 30-min | -0.45% | 37% | 166 |
| 60-min | -0.86% | 36% | 174 |
| to close | 0.00% | 48% | 177 |
| Middle 50% of LIPO reactions | -4.06% to +1.68% |
|---|---|
| Median reaction (30-min) | -0.45% |
| Measured reactions | 177 |
Half of all Lipella Pharmaceuticals Inc. news events land between -4.06% and +1.68% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LIPO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LIPO's baseline. Nothing else.
Recent LIPO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K LIPELLA PHARMACEUTICALS For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | — | -7.71% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +10.00% | +15.88% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -10.34% | |
| Form 10-Q LIPELLA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -8.12% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Oct 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.64% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -6.34% | -0.09% | |
| Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus | Press release | GlobeNewswire | -6.34% | -0.09% | |
| Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus | Press release | PR Newswire | +0.00% | -2.31% | |
| Form 10-Q LIPELLA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.52% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +7.10% | +24.44% | |
| Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting | Press release | GlobeNewswire | +6.07% | +24.44% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | -6.06% | -33.33% | |
| Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market | Press release | GlobeNewswire | +0.33% | -8.33% | |
| Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology | Press release | GlobeNewswire | +0.00% | -6.08% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.08% | |
| Form PRE 14A LIPELLA PHARMACEUTICALS For: Jul 21 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -4.44% | |
| Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development | Press release | GlobeNewswire | -1.71% | +1.54% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: May 16 | SEC filing · Form 8-K | SEC EDGAR | -2.35% | +10.26% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +1.27% | -5.51% | |
| Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting | Press release | GlobeNewswire | +1.27% | -5.51% | |
| Form 10-Q LIPELLA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.27% | -5.51% | |
| Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” | Press release | GlobeNewswire | +0.00% | -3.21% | |
| Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025 | Press release | GlobeNewswire | -7.30% | +5.97% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | — | -0.41% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | — | +9.59% | |
| Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.91% | |
| Form EFFECT LIPELLA PHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | -0.92% | -2.98% | |
| Form D LIPELLA PHARMACEUTICALS | SEC filing · Form D | SEC EDGAR | +0.41% | +4.90% | |
| Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast | Press release | GlobeNewswire | +0.83% | +10.04% | |
| Form 10-K LIPELLA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +0.39% | |
| Form S-3 LIPELLA PHARMACEUTICALS | SEC filing · Form S-3 | SEC EDGAR | — | +0.39% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +5.36% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | +5.63% | |
| Spartan Capital Securities, LLC Announces Key February Transactions | Press release | GlobeNewswire | -0.86% | -6.22% | |
| Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement | Press release | GlobeNewswire | -0.01% | +2.29% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.06% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -0.83% | +6.46% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -4.19% | -6.70% | |
| Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus | Press release | GlobeNewswire | -4.19% | -6.70% | |
| Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus | Press release | GlobeNewswire | -10.52% | -30.60% | |
| Form EFFECT LIPELLA PHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | — | -2.34% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | +4.83% | |
| Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement | Press release | GlobeNewswire | -0.29% | -2.31% | |
| Form D LIPELLA PHARMACEUTICALS | SEC filing · Form D | SEC EDGAR | +4.17% | +1.60% | |
| Form S-3 LIPELLA PHARMACEUTICALS | SEC filing · Form S-3 | SEC EDGAR | +4.17% | +1.60% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -2.24% | -10.92% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | -2.24% | |
| Form 8-K LIPELLA PHARMACEUTICALS For: Dec 27 | SEC filing · Form 8-K | SEC EDGAR | -2.02% | -3.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LIPO section they belong to.
Where else LIPO is measured.
LIPO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lipella Pharmaceuticals Inc.'s median reaction calculated?
Every labeled LIPO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 177 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of LIPO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LIPO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.